1,834 results on '"Domingo Pere"'
Search Results
52. Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV-infected patients on combination antiretroviral therapy (cART). A sub-study of a randomized, double-blind, placebo-controlled study
53. Cost–effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components
54. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study
55. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression : Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
56. Monkeypox (mpox): Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study
57. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
58. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines
59. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss
60. High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients
61. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
62. Author Correction: HIV and antiretroviral therapy-related fat alterations
63. HIV and antiretroviral therapy-related fat alterations
64. Characteristics and outcome of spontaneous bacterial meningitis in patients with diabetes mellitus
65. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
66. Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study
67. Acute Bacterial Meningitis in Healthy Adult Patients: A Prospective Cohort Study
68. Grau de commutativitat de grups finitament generats
69. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015
70. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
71. Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index
72. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection
73. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
74. Acute Viral Meningitis
75. Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals
76. Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant
77. IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status
78. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial
79. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
80. Expression of human and mouse adenine nucleotide translocase (ANT) isoform genes in adipogenesis
81. Perfil de seguridad de dolutegravir
82. Longitudinal Neuropsychological Profiles of Post COVID-19 Condition: Reassessing Individuals with Initial Cognitive Complaints in a 1-Year Follow-Up Study Background
83. Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial
84. Incidence of hypertension and blood pressure changes in persons with human immunodeficiency virus (HIV) at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir : a post-hoc analysis of the 96-week randomised NEAT-022 trial
85. Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial
86. Obesity-related Single-Nucleotide Polymorphisms and Weight Gain Following First-Line Antiretroviral Therapy
87. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por el virus de la inmunodeficiencia humana
88. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
89. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial
90. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations
91. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
92. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia
93. A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
94. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
95. Evolution of notified sexually transmitted infections in Barcelona during the first wave of the COVID‐19 pandemic
96. Acute Viral Meningitis
97. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
98. Who is lost to follow‐up in HIV care? Assessment of care retention over time and the impact of COVID‐19. Longitudinal analysis of the PISCIS cohort.
99. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
100. Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.